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Sustained virologic response (SVR) after antiviral therapy for recurrent hepatitis C virus (HCV) infection in liver transplant (LT)
recipients is consistently lower than that achieved in non-LT patients. We evaluated efficacy and safety of pegylated interferon
(IFN) and ribavirin (RBV) therapy in LT recipients with recurrent HCV and factors associated with SVR. All subjects with
histologic evidence of recurrent HCV were intended to be treated for 48 weeks with full-dose pegylated IFN; target dose of RBV
was 800 mg/day. Thirty-five LT recipients with recurrent HCV, median age 48.5 years, 77% genotype 1, and median
pretreatment HCV RNA 6.4 log10 IU/mL were treated between January 2000 and February 2006. Antiviral therapy was
discontinued prematurely in 15 subjects as a result of adverse events. Median overall treatment duration was 46 weeks. Early
virologic response at week 12 was seen in 17 (49%) and an end-of-treatment virological response in 19 (54%) patients. SVR
was achieved in 13 patients (37%), and all 9 patients followed for 1 year after treatment had durable response. Patients with
SVR had significantly lower pretreatment HCV RNA (5.7 vs. 6.5 log10 IU/mL, P  0.003), more likely to have a week 12
virological response (85% vs. 27%, P  0.0009) and received higher cumulative doses of pegylated IFN (75% vs. 33%, P 
0.029) and RBV (90% vs. 26%, P  0.016) compared with patients whose disease did not respond to therapy. In conclusion,
SVR was achieved in 37% of patients with recurrent hepatitis C after LT. Similar to non-LT patients, those with lower
pretreatment HCV RNA, a week 12 virological response, and pegylated IFN and RBV dose adherence were more likely to
achieve SVR. Liver Transpl 13:1100-1108, 2007. © 2007 AASLD.
Received October 25, 2006; accepted January 2, 2007.
See Editorial on Page 1088
Hepatitis C is the major indication for liver transplan-
tation (LT) in western countries. Reinfection with hep-
atitis C virus (HCV) after LT is a universal phenomenon
and is characterized by accelerated histological pro-
gression, with 6-23% of patients developing cirrhosis
after a median of 3-4 years after LT.1-5 Currently, there
is no consensus on the optimal timing for initiation of
antiviral therapy, duration of treatment, or dose regi-
men for patients with recurrent hepatitis C. Results of
preemptive antiviral therapy initiated within the first
few weeks after LT to prevent or ameliorate recurrent
hepatitis C have been disappointing, with sustained
virologic response (SVR) rates ranging 10-20% and as
many as 50% of patients discontinuing treatment as a
result of adverse events.6-9 Therefore, most investiga-
tors have focused on the treatment of established re-
current hepatitis C.
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More recent studies that used the combination of
pegylated interferon (IFN) and ribavirin (RBV) have re-
ported higher SVR rates of 25-40% in LT recipients with
recurrent HCV.10-13 However, most of these studies in-
cluded small numbers of patients (range 12-54 pa-
tients), and the duration of posttreatment follow-up
was short (6 months). Furthermore, adverse events that
are unique to LT recipients and the use of growth fac-
tors were not described in detail. Retrospective analy-
ses of treatment trials in nontransplant patients have
demonstrated a strong correlation between SVR rate
and dose adherence,14 but the importance of dose ad-
herence and treatment outcomes in LT recipients has
not been described. The aim of our study was to evalu-
ate the efficacy and safety of the combination of pegy-
lated IFN and RBV in LT recipients with histological
recurrence of hepatitis C. In addition, we set out to
identify baseline and treatment related factors associ-
ated with SVR.
METHODS
Patient Population and Data Collection
Medical records of all adult patients (18 years) who
underwent LT for chronic HCV at the University of
Michigan Health System were reviewed. Patients with
recurrent HCV and received pegylated IFN and RBV
combination therapy for recurrent HCV between Janu-
ary 2000 and February 2005 were included. Patients
who received standard IFN with or without RBV or pe-
gylated IFN monotherapy were excluded. Recurrent
hepatitis C was defined by the presence of histological
features of hepatitis C and Ishak fibrosis score 1 in
patients with detectable HCV RNA and abnormal liver
biochemistries after LT and the absence of rejection or
biliary obstruction at biopsy and imaging.15 Pretreat-
ment biopsies were performed in all patients. Liver bi-
opsies were repeated during antiviral treatment in pa-
tients who had worsening liver biochemistries to
exclude rejection or other etiologies. All biopsy samples
were subsequently reviewed in a blinded fashion by a
single pathologist (J.K.G.). Pretreatment biopsy sam-
ples were graded for inflammation and fibrosis with the
classification of Ishak et al.16 Data were censored in
March 2006.
Data on demographics (age, gender, race/ethnicity)
and Model for End-Stage Liver Disease score at the time
of transplant, history of IFN-based treatment before LT,
and donor age were recorded. Information collected be-
tween LT and initiation of pegylated IFN and RBV ther-
apy included calcineurin inhibitor use, dose and dura-
tion of corticosteroids, use of mycophenolate mofetil,
episodes of rejection, and rejection treatment. Pretreat-
ment liver histology, HCV RNA level, HCV genotype,
blood counts (hemoglobin, white blood cells, absolute
neutrophil count [ANC], platelet count), liver biochem-
istries (albumin, aspartate and alanine aminotransfer-
ase [AST and ALT], alkaline phosphatase [ALP], total
bilirubin, creatinine), and prothrombin time expressed
as international normalized ratio were also recorded.
The cumulative dose of pegylated IFN and RBV re-
ceived, and the timing and reasons for dose reductions
and discontinuations, occurrence of adverse events,
and use of growth factors and antidepressants were
reviewed.
Immunosuppression
Standard immunosuppression at our institution con-
sisted of triple therapy with tacrolimus or cyclosporine,
mycophenolate mofetil, and corticosteroids. Prednisone
was discontinued at month 6 in patients with recurrent
HCV.
HCV RNA Assays
Quantitative polymerase chain reaction assays were
performed to detect HCV RNA at weeks 0, 12, and 24,
then every 24 weeks during treatment and at months 6
and 12, and annually after completion of treatment.
Before 2004, the Cobas Amplicor Monitor (Roche Mo-
lecular Diagnostics, Pleasanton, CA) with a lower limit
of detection of 600 IU/mL was used; thereafter, the
Taqman system (Roche Molecular Diagnostics) with a
lower limit of detection of 50 IU/mL was used.
Treatment Protocol
All patients received a combination of pegylated IFN
(alfa 2a [2a] or alfa 2b[2b]) and RBV. The intended
dose of pegylated IFN-2b was 1.5 g/kg/week, and the
intended dose of pegylated IFN-2a was 180 g/week,
whereas the intended dose of RBV was 800 mg/day in 2
divided doses. Seventeen patients (49%) initiated treat-
ment at 50% of pegylated IFN dose with escalation to
intended dose as tolerated over a 4-6-week period. The
intended duration of treatment was 48 weeks regard-
less of HCV genotype. The cumulative dose of pegylated
IFN and RBV received was expressed as a percentage of
the total intended dose. End-of-treatment response was
defined as undetectable HCV RNA at the end of treat-
ment and SVR as undetectable HCV RNA 24 weeks after
the completion of treatment. Early virologic response
(EVR) was defined as 2 log drop or undetectable HCV
RNA at week 12 of treatment.
Blood counts and liver biochemistries were moni-
tored at weeks 0, 1, 2, 4, 6, and 8 and every 4 weeks
until the end of treatment and at follow-up weeks 12
and 24. Thyroid-stimulating hormone and HCV RNA
levels were tested before treatment and every 12 weeks
during treatment, and at follow-up weeks 12, 24, and
48, and annually thereafter. Adverse events and labo-
ratory values were reviewed by transplant nurses in
consultation with a transplant hepatologist every 2-4
weeks, and the patients were reassessed in clinic by a
transplant hepatologist every 12 weeks.
Between 2000 and 2003, pegylated IFN and RBV were
initiated at 50% or 75% of intended doses, and cytope-
nias were managed by dose reduction and/or discon-
tinuation of pegylated IFN and/or RBV according to
recommendations in the package insert. Growth factors
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were rarely administered, and when they were, it was
mostly in patients with persistent anemia or neutrope-
nia despite dose reductions. During the last 2 years,
treatment was initiated at full dose in most patients,
and growth factors (i.e. granulocyte colony-stimulating
factor, erythropoietin) were usually used before dose
reduction. For analysis of cytopenias, anemia was de-
fined as 2 g drop in hemoglobin from pretreatment
value or hemoglobin 10 g/dL. Neutropenia was de-
fined as ANC 1,000 mm3 and thrombocytopenia as
platelet count 50,000/mm3. Emotional side effects
were managed expectantly with dose reductions and/or
antidepressants as clinically needed.
Statistical Analysis
All patients were included in the analysis of response.
Patients who discontinued treatment early and had de-
tectable HCV RNA when treatment was withdrawn were
considered to have disease nonresponsive to therapy.
Patients who had undetectable HCV RNA at the end of
treatment and did not have HCV RNA available at the
end of 6-month follow-up were considered as not
achieving SVR. Continuous variables were expressed as
median and range and categorical variables were ex-
pressed as proportions. The Mann-Whitney test was
used to compare the continuous variables, and the 2
and Fisher exact tests were used to compare categorical
characteristics of patients with and without SVR. P
value of  0.05 was considered significant. Multivari-
able analysis was performed with baseline log HCV
RNA, EVR (week 12 response), cumulative dosages of
pegylated IFN and RBV received, and use of growth




Table 1 shows the baseline characteristics of the 35
patients that were eligible for this study. All the patients
had increased AST and ALT before antiviral treatment.
Most of the patients were men (77%) and white (89%).
The median age at the time of LT was 48.5 years (range
36-62 years). All patients received deceased donor liver
allograft, and the median donor age was 31 years (range
15-64 years). The median interval from LT to start of
pegylated IFN and RBV therapy was 64 weeks (range
6-518 weeks). Three patients began treatment within
the first 6 months after LT, 10 between 6-12 months, 13
in year 2 after LT, and 9 after year 2 after LT. Nine
patients experienced a single episode of rejection
each, and 1 additional patient had 2 episodes of re-
jection. All patients with rejection responded to cor-
ticosteroid pulses except the last patient, who re-
quired monoclonal antibody for the second episode of
rejection. None of the patients had a rejection episode
within 3 months before initiation of antiviral therapy.
At the time pegylated IFN and RBV therapy was
started, 15 patients were receiving cyclosporine, and
the remaining 20 were receiving tacrolimus. Ten pa-
tients were also receiving mycophenolate mofetil, and
4 patients were still receiving prednisone at the be-
ginning of antiviral therapy. All the patients with re-
jection or autoimmune hepatitis on antiviral treat-
ment were receiving cyclosporine; their trough levels
during treatment were similar to those who did not
have rejection or autoimmune hepatitis.
Most patients (77%) had HCV genotype 1 infection,
and median pretreatment HCV RNA was 6.4 log IU/mL
(range 4.4-7.6 log IU/mL). Although most patients had
compensated liver disease and preserved renal func-
tion, 2 patients had total bilirubin 5 mg/dL, and 5
had a pretreatment serum creatinine 1.2 mg/dL.
Liver biopsy was performed on all patients within a
median of 97 days (range 20-1,063 days) before treat-
ment. Twenty-two patients (63%) underwent a liver bi-
opsy within 6 months before the initiation of antiviral
treatment. The median necroinflammatory score was 7
(range 4-12) and Ishak fibrosis score was 2 (range 1-6).
One patient had cholestatic recurrent hepatitis C.
TABLE 1. Characteristics of Patients
Variable Value
Age (yr) 48.5 (36-62)
Male gender 27 (77%)
White 31 (89%)
Time from LT to start of antiviral
therapy (weeks)
64 (6-518)
Pre-LT HCV treatment 11/17 (64.7%)









Hemoglobin (g/dL) 14.7 (11.6-18.2)
ANC (k/mm3) 2.5 (1.2-7.6)
Platelets (k/mm3) 130 (53-255)
INR 1 (0.8-1.2)
HCV RNA (log10) (IU/mL) 6.4 (4.4-7.6)
Genotype 1 (%) 77
AST (IU/mL) 150 (43-1,433)
ALT (IU/mL) 209 (62-633)
Total bilirubin (mg/dL) 1.0 (0.4-15.1)
Alkaline phosphatase (IU/mL) 132 (71-520)





Ishak fibrosis 2 (1-6)
Abbreviations: LT, liver transplantation; ANC, absolute
neutrophil count; INR, international normalized ratio;
HCV, hepatitis C virus; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; HAI, histological activity
index. Values are presented as median (range), n/n (%), or
n (%).
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Dose and Duration of Treatment Received
The outcomes of the patients are summarized in Figure
1. The median duration of treatment was 46 weeks
(range 3-126 weeks). Twenty patients (57%) completed
80% of intended treatment duration, and 15 (43%)
discontinued treatment early as a result of adverse ef-
fects. Eleven patients (31.4%) received 80% of in-
tended pegylated IFN dose, 13 patients (37%) received
80% of intended RBV dose, and 9 patients (26%) re-
ceived 80% of intended pegylated IFN and RBV dose.
Fourteen (40%), 17 (49%), and 12 (34%) patients re-
ceived 60% of pegylated IFN, RBV, and combination of
pegylated IFN and RBV doses. The RBV dose received
did not correlate with baseline creatinine clearance (r 
0.2, P  0.18).
Virologic and Biochemical Responses
After 12 weeks of antiviral treatment, 15 patients had
undetectable HCV RNA, and 2 additional patients had
2 log decrease in HCV RNA level, giving an EVR rate of
49% (17 of 35). Nineteen patients (54%) had end-of-
treatment virologic response, and 13 (37%) achieved
SVR. Of the 13 patients with SVR, 11 (85%) had EVR.
Normalization of AST and ALT was observed in 19
patients (54%) and 13 patients (37%), respectively, at
the end of treatment and in 11 patients (31%) and 8
patients (23%), respectively, after 24 weeks of post-
treatment follow-up.
Four patients had moderately increased pretreat-
ment liver biochemistries (AST 332-1,433 IU/mL, ALT
291-633 IU/mL, ALP 270-520 IU/mL) and were jaun-
diced (total bilirubin 2.4-15.1 mg/dL). One patient re-
ceived treatment for 50 weeks with normalization of
AST, ALP, and total bilirubin at the end of treatment.
This patient had a 2 log decrease in HCV RNA at week
12; however, HCV RNA remained detectable throughout
the course of treatment. Despite persistent viremia,
AST and ALT remained normal 1 year after treatment
was stopped. Another patient had marked reduction in
AST (594 to 111 IU/mL), ALT (536 to 81 IU/mL), ALP
(520 to 226 IU/mL) and total bilirubin (3.9 to 1.5 mg/
dL). However, treatment was discontinued at week 8
because of disabling myalgias and fatigue with persis-
tently detectable HCV RNA. The other 2 patients had
increased ALP despite some improvement in AST, ALT,
and total bilirubin during treatment. However, treat-
ment was stopped after 6 and 10 weeks in these 2
patients as a result of induction of autoimmune-like
hepatitis.
Factors Associated With SVR
Table 2 compares the characteristics of patients with
and without SVR. Univariate analysis showed that pa-
tients with SVR had significantly lower levels of pre-
treatment HCV RNA level (P  0.003), and had received
significantly higher median doses of pegylated IFN (77%
vs. 33% of intended dose, P  0.029) and RBV (90% vs.
26% of intended dose, P  0.016) compared with pa-
tients without SVR. In addition, patients with SVR
tended to have longer median duration of treatment (48
vs. 20 weeks, P  0.072) compared with patients with-
out SVR. Patients who received 60% of the intended
dosage of both pegylated IFN and RBV dose had higher
rates of SVR (8 of 12, 67%, vs. 5 of 23, 22%, P  0.037)
than those who received 60% of one or both medica-
tions. Patients with SVR were also more likely to have
EVR (85% vs. 27%, P  0.0009), anemia (92% vs. 59%,
P  0.049), and use of erythropoietin (38% vs. 9%, P 
0.04) than those without SVR. However, none of these
factors remained significant on multivariable analysis.
Long-Term Outcomes of Patients Who
Completed Antiviral Therapy
Nine patients (69%) with SVR were followed for a me-
dian of 25.2 months (range 14.4-40.8 months) after
completion of treatment, and none of them had late
virological relapse. One of these 9 patients developed an
abrupt increase in aminotransferases 2 years after suc-
cessful completion of treatment with liver histology sug-
gestive of autoimmune hepatitis. Azathioprine and
prednisone were added to the immunosuppression reg-
imen, resulting in improvement of aminotransferases.
This patient was receiving cyclosporine, azathioprine,
and 7.5 mg/day prednisone and had normal amin-
otransferases and undetectable HCV RNA at the last
follow-up visit, 30 months after completion of pegylated
IFN and RBV treatment, and 12 months after reinitia-
tion of prednisone and azathioprine.
Another patient, who discontinued treatment after 17
weeks as a result of severe neutropenia and myalgias,
had undetectable HCV RNA at the end of treatment
underwent retransplantation for severe cholestasis due
to an unidentified cause 13 months after completion of
treatment. This patient had undetectable HCV RNA 2
years after retransplantation.
Figure 1. Outcomes of patients receiving antiviral therapy.
EVR, early virological response; ETR, end-of-treatment re-
sponse; SVR, sustained virological response.
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Adverse Events
Cytopenias
Cytopenias were the most common adverse event that
necessitated dose adjustments, treatment discontinu-
ation, and/or use of growth factors. Neutropenia was
observed in 21 (60%) of 35 patients, and 10 patients
(48%) required dose reduction of pegylated IFN, despite
the use of granulocyte colony-stimulating factor in 6
(29%) of these 21 patients. Anemia was observed in 25
(71%) of 35 patients, and 13 patients (52%) required
dose reduction of RBV despite the use of erythropoietin
in 7 (28%) of these 25 patients.
Two patients developed thrombocytopenia. One pa-
tient had platelet counts 5,000/mm3 and developed
spontaneous subdural hematoma that resulted from
idiopathic thrombocytopenic purpura; this patient’s
course has been reported previously.17 The other pa-
tient’s platelet count varied between 49,000 and
57,000/mm3, and the patient did not experience any
bleeding or dose adjustment.
Other adverse effects
Fifteen patients (42%) experienced depression requir-
ing antidepressants. Treatment was discontinued in 2
patients who required psychiatric hospitalization for
suicidal ideation in one and suicidal attempt in the
other. Both patients improved and have remained emo-
tionally stable 21 and 36 months after discontinuation
of treatment.
Three patients developed infections during the course
of treatment. Two patients had uncomplicated urinary
tract infection and were managed as outpatients with
antibiotic therapy. ANC at the time of diagnosis of in-
fection were 1.8 k/mm3 and 3.8 k/mm3. One patient
with genotype 3 developed a dilated cardiomyopathy
that led to bowel ischemia with gastrointestinal bleed-
ing, renal failure, and sepsis at week 12 of antiviral
therapy. After a 3-month hospitalization, this patient’s
cardiac function recovered. She remained HCV RNA
negative with good synthetic function of the allograft 15
months after discontinuation of antiviral therapy.
Rejection and autoimmune hepatitis
Four patients experienced worsening liver biochemis-
tries with features of rejection/autoimmune hepatitis
on repeat liver biopsies, which led to early discontinu-
ation of antiviral therapy. Patient 1 was a 45-year-old
man who initiated antiviral therapy 76 weeks after LT.
Trough cyclosporine level during the course of treat-
ment varied between 72 and 90 ng/mL. The pretreat-
ment liver biopsy results revealed a histological activity
index (HAI) of 6 and Ishak fibrosis score of 2. Serum
AST, ALT, and bilirubin levels increased markedly
within 6 weeks of starting pegylated IFN and RBV treat-
ment (Fig. 2a). Analysis of liver biopsy samples showed
TABLE 2. Comparison of Patients With and Without Sustained Virological Response
Variable No SVR (N  22) SVR (N  13) P value
Recipient and donor factors
Recipient age at LT (yr) 48 (42-62) 51 (36-62) 0.52
MELD at LT 16 (11-28) 15 (10-20) 0.29
Donor age (yr) 42.5 (15-64) 25 (17-56) 0.37
Pretreatment histology and laboratory results
HAI 7 (5-12) 5 (3-11) 0.2
Ishak fibrosis 2 (1-5) 2 (1-3) 0.3
Genotype 1 (%) 85% 71% 0.4
Log10 HCV RNA (IU/mL) 6.5 (5.5-7.6) 5.6 (4.4-7) 0.003
ALT (IU/mL) 225 (63-633) 168 (62-490) 0.24
AST (IU/mL) 155 (43-1,433) 110 (52-352) 0.09
ALP (IU/mL) 136 (71-520) 106 (72-226) 0.2
Total bilirubin (mg/dL) 1 (0.3-15) 0.9 (0.7-2.2) 0.19
Creatinine (mg/dL) 1 (0.9-1.6) 1.1 (0.8-1.4) 0.6
Treatment-related factors
Treatment duration (weeks) 20 (3-126) 48 (13-102) 0.072
Peg IFN received (%) 33 (4-180) 75 (20-130) 0.029
RBV received (%) 26 (6-114) 90 (14-160) 0.016
Early virologic response (week 12) 6 (27%) 11 (85%) 0.0009
Anemia 13 (59%) 12 (92%) 0.049
Use of erythropoietin 2 (9%) 5 (38%) 0.04
Neutropenia 12 (57%) 9 (69%) 0.4
Use of granulocyte colony-stimulating factor 3 (14%) 3 (24%) 0.25
Abbreviations: SVR, sustained virological response; MELD, Model for End-Stage Liver Diseases; HAI, histological activity
index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; IFN, interferon; RBV,
ribavirin. Upper limit of normal: AST 40 IU/mL; ALT 40 IU/mL; ALP 120 mg/dL; total bilirubin 1.2 mg/dL; creatinine 1.0
mg/dL. Values are presented as median (range), n/n (%), or n (%) unless indicated otherwise. Mann-Whitney test and
2/Fisher exact were used to compare the continuous and categorical variables in 2 groups.
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features of acute cellular rejection; antiviral therapy
was stopped, and rejection was treated with pulse in-
travenous corticosteroids. Results of a subsequent liver
biopsy 2 weeks later showed resolution of rejection, but
there were persistent features of lobular and interface
hepatitis with prominent plasma cell infiltrates. This
patient was switched from cyclosporine to tacrolimus
and was maintained on corticosteroids for 1 year, re-
sulting in normalization of AST and total bilirubin.
Patient 2 was a 52-year-old woman who initiated an-
tiviral therapy 181 weeks after LT. Her pretreatment
biopsy findings revealed an HAI of 9 and Ishak fibrosis
score of 2. Serum AST and ALT levels increased after 12
weeks of pegylated IFN and RBV therapy (AST 51-309
IU/mL, ALT 46-194 IU/mL, ALP 117-1,273 mg/dL, and
total bilirubin 1-9 mg/dL), and the results of a repeat
liver biopsy showed acute cellular rejection with evi-
dence of mildly active recurrent hepatitis C. Trough
cyclosporine level during treatment ranged 82-106 ng/
mL. Pegylated IFN and RBV were discontinued; the pa-
tient was treated with intravenous pulse corticosteroid,
and cyclosporine was switched to tacrolimus. Pred-
nisone was tapered off over a period of 10 months with
improvement in serum aminotransferase levels.
Patient 3 was a 45-year-old man who began antiviral
therapy 6 weeks after LT because of clinical and bio-
chemical features of an acute hepatitis. The pretreat-
ment liver biopsy sample had a HAI of 8 and Ishak
fibrosis score of 2. At the beginning of treatment, ALT

















































































































































Figure 2A and B. Serial changes
in liver chemistries in patients 1
and 3 with rejection and autoim-
mune hepatitis after initiation of
antiviral therapy.
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respectively, while ALP was normal. Total bilirubin
peaked at 23 mg/dL at week 4 but dropped to 6.1
mg/dL by week 8. ALT levels also decreased over the
first 8 weeks. However, ALP showed a consistent in-
crease. At week 10, ALT started to increase (Fig. 2b).
Analysis of repeat liver biopsy samples revealed evi-
dence of severe chronic hepatitis with abundant plasma
cells resembling autoimmune hepatitis. Trough cyclo-
sporine levels remained at 80-82 ng/dL during the
course of treatment. Antiviral therapy was stopped,
prednisone dose was increased from 5 to 15 mg daily,
and azathioprine was added with clinical and biochem-
ical improvement.
Patient 4 was a 50-year-old man who initiated anti-
viral therapy 35 weeks after LT. Analysis of pretreat-
ment liver biopsy samples showed minimal lobular hep-
atitis and increased portal fibrosis consistent with
Ishak fibrosis score of 2. Arteries showed foam cell
changes. There was no evidence of acute rejection or
ductopenia. AST and ALT remained stable; however,
ALP increased from 326 to 544 IU/mL after 4 weeks of
treatment, and bilirubin increased from 7.7 to 9.5
mg/dL at week 5. Repeat liver biopsy samples showed
cholestasis with bile duct damage consistent with
chronic ductopenic rejection. Antiviral treatment was
discontinued. Trough cyclosporine levels during treat-
ment were 78-87 ng/mL. Cyclosporine dose was in-
creased, and mycophenolate mofetil and prednisone
were continued. Liver biochemistry laboratory values
remained high despite discontinuation of antiviral
treatment. Prednisone was discontinued after 6
months. This patient was maintained on tacrolimus
and mycophenolate mofetil with improvement of liver
chemistries.
DISCUSSION
In this single-center study of 35 LT recipients with re-
current HCV treated with pegylated IFN and RBV, 37%
achieved SVR despite the need for frequent dose reduc-
tions and early discontinuations. To date, there are 7
published studies with 20 patients evaluating the ef-
ficacy of pegylated IFN and RBV in the treatment of
recurrent HCV after LT. SVR in these studies ranged
31-45%.10,11,18-22 These results are markedly im-
proved over randomized controlled trials of pegylated
IFN monotherapy that reported SVR of 8% and 12%
when used preemptively and for treatment of estab-
lished disease after LT.23 Recently, a systematic review
of IFN-based combination therapy for recurrent HCV
showed SVR of 27% (95% confidence interval [95% CI],
23-31) for pegylated IFN and RBV and 24% (95% CI,
20-27) for standard IFN and RBV.24 Compliance to pe-
gylated IFN and RBV therapy was poor, with only 21%
(95% CI, 9%-34%) maintaining the full dose of pegy-
lated IFN and RBV vs. 33% (95% CI, 28%-38%) for
standard IFN and RBV.24
The rates of early treatment discontinuation and dose
reduction of pegylated IFN and RBV varied from 11-
37% to 30-60%, respectively. Berenguer et al.21 re-
ported an early treatment discontinuation rate of 40%
as a result of adverse effects in their study of 67 pa-
tients who were treated with standard IFN (n  31) or
pegylated IFN (n  36) and RBV. In our study, 43%
patients discontinued antiviral treatment early as a re-
sult of adverse events. Fifty-seven percent of the pa-
tients were able to complete at least 80% of the intended
duration of therapy; however, similar to other reports,
only 26% of patients were able to tolerate at least 80% of
the desired dose of pegylated IFN and RBV.
The target dose of pegylated IFN-2a 180 g every
week and pegylated IFN-2b 1.5 g/kg every week in
the present study was similar to that used in the non-
transplant setting. The lower target dose for RBV (800
mg/day) was chosen because most LT patients have
lower baseline hemoglobin and some degree of renal
insufficiency. Only 3 of 20 patients were able to achieve
a RBV dosage of 1,000-1,200 mg/dL in a pilot study of
treatment of recurrent HCV with pegylated IFN-2b and
RBV.10
Factors associated with SVR after IFN and RBV ther-
apy in post-LT patients are not well established because
of the limited size of prior studies and the low response
rate. In a pilot study of 20 patients, EVR but not dose of
pegylated IFN and RBV received was predictive of
SVR.10 In another study of 67 patients treated with
combination of standard or pegylated IFN and RBV,
80% dose of RBV,  80% overall dose and duration
(80/80/80 rule), use of erythropoietin, and EVR were
statistically significant predictors of SVR on univariate
analysis.21 However, only EVR was predictive of SVR on
multivariate analysis. Similarly, Wang et al.,24 in their
systematic review of IFN-based combination therapy for
recurrent HCV, found that genotype 1 and prior antivi-
ral therapy after LT were statistically significantly as-
sociated with lack of SVR in univariate analysis of trials
on pegylated IFN  RBV, but drug dosage, use of growth
factors, interval from LT, and duration of therapy were
not associated with SVR. However, patients who re-
ceived 60% of pegylated IFN and RBV had higher rates
of SVR.
In this study, lower pretreatment HCV RNA, EVR,
higher cumulative dose of pegylated IFN and RBV, ane-
mia, and use of erythropoietin were associated with
SVR on univariate analysis. It should be pointed out
that anemia and use of erythropoietin was related to the
higher cumulative dose of RBV. However, none of these
factors was predictive of SVR by multivariate analysis,
presumably as a result of the small sample size and
their colinearity.
Although delayed viral relapse after SVR in immuno-
competent individuals is rare, there are no data on the
durability of response after SVR in immunosuppressed
individuals.25,26 None of the patients in this study ex-
perienced viral relapse, including 9 patients followed for
1 year and 5 patients for 2 years after completion of
antiviral treatment. These data suggest that durable
responses are possible in LT recipients.
IFN treatment is associated with an increased risk of
rejection in transplant patients. The risk is higher in
renal transplant patients; the risks reported in LT pa-
tients vary. Two retrospective studies reported an 11%
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and 35% rejection rate in patients with histologically
proven recurrent hepatitis C who received IFN-based
combination therapy.27,28 However, 2 prospective ran-
domized controlled trials evaluating pegylated IFN
monotherapy in LT patients treated preemptively or for
established HCV recurrence reported similar rates of
rejection in the treated patients and untreated con-
trols.23
Four patients (11%) in the current study had wors-
ening liver biochemistries within 12 weeks of the onset
of IFN therapy. Analysis of repeat liver biopsy samples
showed acute rejection in 2 patients, autoimmune hep-
atitis in 1 patient, and chronic ductopenic rejection in 1
patient. All 4 patients responded to corticosteroid treat-
ment. An additional patient with SVR had de novo au-
toimmune hepatitis 2 years after completion of antiviral
therapy, which responded to reintroduction of pred-
nisone and azathioprine without virological relapse. Al-
though none of these patients experienced graft loss,
this experience highlights the potential risks of IFN
therapy in liver transplant patients and the importance
of liver histology in determining the cause of abnormal
liver chemistries in LT patients. De novo autoimmune
hepatitis has been reported in 0.4-3.4% of transplant re-
cipients without previous autoimmune hepatitis.29,30
Only 9 cases of de novo autoimmune hepatitis in patients
with recurrent HCV after LT had been reported.12,29-33
Four of them were receiving IFN-based antiviral therapy
at the time of diagnosis,12,32,33 and one patient developed
progressive graft failure despite discontinuation of antivi-
ral treatment requiring retransplantation.29
The limitations of this study include retrospective
design, small number of patients, heterogeneity in the
titration of the pegylated IFN and RBV dose up to target
dose, and use of growth factors in the management of
cytopenias.
In conclusion, this study has shown that combina-
tion pegylated IFN and RBV therapy can result in SVR
of 37% in patients with recurrent HCV after LT despite
the need for dose reductions and early discontinuation
in 43% of patients. Patients with low pretreatment HCV
RNA and EVR, and those who received higher cumula-
tive dose of pegylated IFN and RBV were more likely to
achieve SVR. Once SVR is achieved, the response ap-
peared to be durable. However, serious adverse events
were common, which highlights the need for careful
laboratory and clinical assessment. Prospective studies
are needed to confirm the applicability of the early stop
rule on the basis of week 12 virologic response and the
cost-effectiveness of prophylactic growth factors in this
setting.
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